Spots Global Cancer Trial Database for mesothelioma
Every month we try and update this database with for mesothelioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | NCT05278975 | Malignant Pleur... Malignant Pleur... Mesothelioma Mesotheliomas P... Mesothelioma; L... Pleural Effusio... | RSO-021 | 18 Years - | RS Oncology LLC | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays | NCT02834234 | Peritoneal Meso... | comparative gen... | 18 Years - | Hospices Civils de Lyon | |
| Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | NCT02062632 | Esophageal Carc... Hypopharyngeal ... Laryngeal Carci... Lymphoma Mesothelioma Metastatic Mali... Metastatic Mali... Metastatic Mali... Non-Small Cell ... Sarcoma Small Cell Lung... Thymic Carcinom... Thymoma Thyroid Gland C... | Doxepin Hydroch... Placebo Quality-of-Life... Questionnaire A... | 18 Years - | Mayo Clinic | |
| A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | NCT05571839 | Cutaneous Melan... Non-small Cell ... Colorectal Neop... Pancreatic Neop... Mesothelioma | SGN-BB228 | 18 Years - | Seagen Inc. | |
| UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC | NCT04940637 | Lung Cancer Mesothelioma | niraparib and d... | 18 Years - | University of Turin, Italy | |
| Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | NCT02610140 | Mesothelioma | Anetumab ravtan... Vinorelbine | 18 Years - | Bayer | |
| GPC3/Mesothelin-CAR-γδT Cells Against Cancers | NCT06196294 | Pancreas Cancer Lung Cancer Liver Cancer Mesothelioma CAR-T Cell Ther... Solid Tumor, Ad... | Cell therapy fo... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) | NCT01204203 | Mesothelioma | Zometa | 19 Years - | University of Alabama at Birmingham | |
| A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) | NCT04153565 | Mesothelioma | Pembrolizumab Pemetrexed Cisplatin | 20 Years - | Merck Sharp & Dohme LLC | |
| Mesothelioma Avastin Plus Pemetrexed-cisplatin Study | NCT00651456 | Mesothelioma | Standard Chemot... Standard Chemot... | 18 Years - 75 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | NCT03638206 | B-cell Acute Ly... Lymphoma Myeloid Leukemi... Multiple Myelom... Hepatoma Gastric Cancer Pancreatic Canc... Mesothelioma Colorectal Canc... Esophagus Cance... Lung Cancer Glioma Melanoma Synovial Sarcom... Ovarian Cancer Renal Carcinoma | CAR-T cell immu... | 4 Years - 70 Years | Shenzhen BinDeBio Ltd. | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma | NCT04214015 | Mesothelioma Mesothelioma Ma... Mesothelioma; L... Mesotheliomas P... Mesothelioma Pe... Mesothelioma; L... Mesothelioma; O... | No intervention | - | ProgenaBiome | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma | NCT00859469 | Mesothelioma | Oxaliplatin Gemcitabine | 18 Years - | Columbia University | |
| An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma | NCT00685204 | Mesothelioma | Milataxel | 18 Years - | Taxolog Inc. | |
| Studying the Clinical Trial Experiences of Patients With Mesothelioma | NCT05819580 | Mesothelioma | 18 Years - | Power Life Sciences Inc. | ||
| Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | NCT05245500 | Mesothelioma Non Small Cell ... Malignant Perip... Solid Tumor Pancreatic Aden... Advanced Solid ... | MRTX1719 | 18 Years - | Mirati Therapeutics Inc. | |
| Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | NCT02758587 | Carcinoma, Non-... Mesothelioma Pancreatic Neop... | Defactinib Pembrolizumab | 18 Years - | NHS Greater Glasgow and Clyde | |
| Olaparib in People With Malignant Mesothelioma | NCT03531840 | Mesothelioma | Olaparib ClinOmics | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Olaparib in People With Malignant Mesothelioma | NCT03531840 | Mesothelioma | Olaparib ClinOmics | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD) | NCT00748085 | Lung Cancer Mesothelioma | CryoSpray Ablat... | 18 Years - | CSA Medical, Inc. | |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors | NCT06336148 | Solid Tumor | ACTM-838 | 18 Years - | Actym Therapeutics, Inc. | |
| Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma | NCT03867578 | Mesothelioma Peritoneal Meso... | HR-MRI Standard CT Ima... Ultrasound | 18 Years - | University of Chicago | |
| Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma | NCT04166734 | Advanced Malign... | Pembrolizumab Stereotactic Bo... | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | NCT05041062 | Mesothelioma Peritoneal Meso... | Nivolumab Ipilimumab | 18 Years - | University of Chicago | |
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | NCT04334759 | Mesothelioma Pleural Mesothe... Malignant Pleur... | Durvalumab Standard Chemot... Ipilimumab and ... | 18 Years - | PrECOG, LLC. | |
| Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy | NCT00004547 | Abdominal Neopl... Colonic Neoplas... Mesothelioma Peritoneal Neop... | Surgery Continuous hype... Postoperative d... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer | NCT00325494 | Pancreatic Canc... Mesothelioma Ovarian Cancer Non-Small Cell ... | MORAb-009 | 18 Years - | Morphotek | |
| An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma | NCT00787410 | Mesothelioma | ZD1839 | 18 Years - | AstraZeneca | |
| Chest Wall Motion Analysis in Disease | NCT02958683 | Mesothelioma Lung Neoplasms Surgery Cystic Fibrosis Pectus Carinatu... Pectus Excavatu... Empyema, Pleura... Pulmonary Disea... | Chest wall moti... | 16 Years - | Heart of England NHS Trust | |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | NCT05451849 | Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ... | TC-510 Fludarabine Cyclophosphamid... | 18 Years - | TCR2 Therapeutics | |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | NCT03935893 | Gastric Cancer Colorectal Canc... Pancreatic Canc... Sarcoma Mesothelioma Neuroendocrine ... Squamous Cell C... Merkel Cell Car... Mismatch Repair... Microsatellite ... | Tumor Infiltrat... Fludarabine + C... | 18 Years - 75 Years | University of Pittsburgh | |
| A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors | NCT00528619 | Neoplasms | Sunitinib, Peme... | 18 Years - | Pfizer | |
| Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma | NCT01950572 | Mesothelioma Thymoma Pancreatic Neop... Biliary Tract N... Stomach Neoplas... | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | NCT01362790 | Mesothelioma Adenocarcinoma ... Pancreatic Neop... | Pentostatin Cyclophosphamid... SS1(dsFv)PE38 -... SS1(dsFv)PE38 -... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | NCT03881488 | Locally Advance... Metastatic Canc... Non-small Cell ... Small Cell Lung... Mesothelioma Melanoma Head and Neck C... | CTX-471 Pembrolizumab (... | 18 Years - | Compass Therapeutics | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Combination Gene Transfer and Chemotherapy | NCT01119664 | Mesothelioma | SCH 721015 | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma | NCT01950572 | Mesothelioma Thymoma Pancreatic Neop... Biliary Tract N... Stomach Neoplas... | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours | NCT04375267 | Clinical Trial,... Neuroendocrine ... Thymoma Mesothelioma | 177Lu-DOTA-TATE... | 18 Years - | Vastra Gotaland Region | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | NCT03436732 | Mesothelioma | LMB-100 SEL-110 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | NCT03319537 | Mesothelioma | pevonedistat Pemetrexed and ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Do Your Genes Put You at a Higher Risk of Developing Mesothelioma | NCT01590472 | Mesothelioma | 18 Years - | Wake Forest University Health Sciences | ||
| Do Your Genes Put You at a Higher Risk of Developing Mesothelioma | NCT01590472 | Mesothelioma | 18 Years - | Wake Forest University Health Sciences | ||
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide | NCT00629343 | Soft Tissue Sar... Mesothelioma | Azacitidine In ... | 18 Years - | Columbia University | |
| Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | NCT00137826 | Mesothelioma | Erlotinib Bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma | NCT04429204 | Mesothelioma | Biospecimen Col... Cryosurgery | - | Jonsson Comprehensive Cancer Center | |
| Tomotherapy Treatment for Mesothelioma | NCT00469196 | Mesothelioma | Tomotherapy | 18 Years - | AHS Cancer Control Alberta | |
| Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication | NCT02511600 | Lung Diseases Mesothelioma | Progel Sealant Talcum Powder Pain Questionna... | 18 Years - | M.D. Anderson Cancer Center | |
| Olaparib in Patients With HRD Malignant Mesothelioma | NCT04515836 | Mesothelioma Homologous Reco... | Olaparib | 18 Years - | University of Chicago | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | NCT03644550 | Mesothelioma | LMB-100 Pembrolizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance | NCT04450043 | Non Small Cell ... Small-cell Lung... Mesothelioma Cognitive Behav... | Run-In Sessions... RCT Transitions... RCT Control Ses... | 21 Years - | Massachusetts General Hospital | |
| A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | NCT03075527 | Mesothelioma | Tremelimumab Durvalumab | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | NCT02611024 | Advanced Solid ... Glioblastoma Soft Tissue Sar... Endometrial Car... Epithelial Ovar... Mesothelioma Gastroenteropan... SCLC Gastric Carcino... Pancreatic Aden... Colorectal Carc... Neuroendocrine ... | Lurbinectedin Irinotecan | 18 Years - | PharmaMar | |
| Cardiac MRI Biomarker Testing (GCC 1618) | NCT02688166 | Breast Cancer Lung Cancer (No... Thoracic Cancer Thymic Cancer Mesothelioma | Complete Cardia... | 18 Years - | University of Maryland, Baltimore | |
| SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | NCT01445392 | Mesothelioma | Multicycle SS1P Pemetrexed Cisplatin Single cycle SS... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| First-in-human Study of S-588210 (S-488210+S-488211) | NCT04316689 | Lung Cancer Head and Neck C... Bladder Cancer Esophageal Canc... Mesothelioma | S-488210 S-488211 | 18 Years - | Shionogi Inc. | |
| Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma | NCT00407459 | Mesothelioma | Bevacizumab, Pe... | 18 Years - | Istituto Clinico Humanitas | |
| A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | NCT05238883 | Gastric Cancer Renal Cell Carc... Melanoma Sarcoma Testicular Germ... Cervical Cancer Mesothelioma Non Small Cell ... Head and Neck S... | HFB200301 Tislelizumab | 18 Years - | HiFiBiO Therapeutics | |
| Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma | NCT00101283 | Mesothelioma | pemetrexed diso... gemcitabine hyd... carboplatin | 18 Years - | Eastern Cooperative Oncology Group | |
| Dose Individualization of Pemetrexed - IMPROVE-I | NCT03656549 | Non Small Cell ... Mesothelioma | Pemetrexed | 18 Years - | Radboud University Medical Center | |
| Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma | NCT05193006 | Peritoneal Mali... | No intervention | 18 Years - 80 Years | Hospices Civils de Lyon | |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | NCT06097728 | Unresectable Pl... | Volrustomig Pemetrexed Carboplatin Cisplatin Nivolumab Ipilimumab | 18 Years - | AstraZeneca | |
| Malignant Mesothelioma - Can we Improve Quality of Life | NCT03068117 | Mesothelioma, M... | Regular Early S... | 18 Years - | Portsmouth Hospitals NHS Trust | |
| A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | NCT01521325 | Mesothelioma Pancreatic Canc... Ovarian Cancer Non-small Cell ... | Amatuximab | 18 Years - | Morphotek | |
| Niraparib Efficacy in Patient With Unresectable Mesothelioma | NCT05455424 | Mesothelioma, M... | Niraparib Oral ... Active Symptom ... | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Pulmonary Interstitial Lymphography in Early Stage Lung Cancer | NCT01188486 | Lung Cancer Lung Cancer Non... Lung Cancer Sma... Mesothelioma | Stereotactic Bo... Computed Tomogr... Cyberknife Trilogy True Beam Iohexol Iodixanol | 18 Years - | Stanford University | |
| Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma | NCT00859469 | Mesothelioma | Oxaliplatin Gemcitabine | 18 Years - | Columbia University | |
| Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | NCT04537715 | All Malignancie... Advanced Malign... Hematologic Mal... Solid Tumor Follicular Lymp... Non-Hodgkin Lym... Diffuse Large B... Epithelioid Sar... Synovial Sarcom... Renal Medullary... Mesothelioma Rhabdoid Tumor | Tazemetostat Itraconazole Tazemetostat Rifampin | 18 Years - | Ipsen | |
| Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis | NCT00454519 | Stomach Neoplas... Colorectal Neop... Neoplasm Metast... Mesothelioma | cytoreductive s... intraoperative ... | 20 Years - 70 Years | Wuhan University | |
| DENdritic Cell Immunotherapy for Mesothelioma | NCT03610360 | Mesothelioma | MesoPher | 18 Years - | Amphera BV | |
| SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | NCT01362790 | Mesothelioma Adenocarcinoma ... Pancreatic Neop... | Pentostatin Cyclophosphamid... SS1(dsFv)PE38 -... SS1(dsFv)PE38 -... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
